A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug

Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.

Closed sign

Bristol-Myers Squibb Co. has terminated the three Phase III studies of its in-house IDO inhibitor BMS-986205 in melanoma, head and neck, and lung cancer – an asset acquired through a high-priced acquisition of Flexus Biosciences Inc. in 2015.

Indoleamine 2,3-dioxygenase (IDO1) is an enzyme that plays an important part in immune response. (Also see "Scrip's Rough Guide...

More from Immuno-oncology

More from Anticancer